Communiqués Alzinova AB

Actions

ALZ

SE0007413455

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,4000 ^SEK	-1,72%		-3,50%	-51,75%

08:26	Alzinova élargit son actionnariat avec un nouvel investisseur	RE
06:31	L’actionnaire principal d’Alzinova vend des actions pour 6,5 millions et souscrit à sa quote-part dans l’émission	FW

Communiqués

01/10	Alzinova broadens its shareholder base with a new institutional investor, while its principal shareholder subscribes for its full pro rata share in the ongoing rights issue	AQ
01/10	Alzinova : The last day of trading in unit rights in Alzinova's rights issue	PU
01/10	The last day of trading in unit rights in Alzinova’s rights issue	AQ
01/10	Alzinova: Supportive early results for diagnostics programme	AQ
30/09	Alzinova : completes study with Amsterdam UMC - results support continued development and partnership discussions in blood-based Alzheimer's diagnostics	PU
30/09	Alzinova completes study with Amsterdam UMC – results support continued development and partnership discussions in blood-based Alzheimer’s diagnostics	AQ
24/09	Alzinova’s Phase II study with ALZ-101 accepted for presentation at international Alzheimer’s conference	AQ
22/09	The subscription period in Alzinovas rights issue of units starts today	AQ
21/09	Alzinova Advances Dual Approach to Alzheimer’s Treatment and Diagnosis as World Alzheimer’s Day Highlights Unmet Need	GL
18/09	Alzinova publishes information memorandum in connection with rights issue of units	AQ
11/09	Alzinova: Phase II study update and SEK51 rights issue	AQ
11/09	Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital	AQ
10/09	The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million	AQ
10/09	Alzinova initiates operational start-up of global Phase 2 study with ALZ-101	AQ
24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ
20/08	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities	AQ
20/08	Alzinova publishes interim report for the period January - June 2026	AQ
07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
24/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
24/06	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
12/06	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
08/06	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ
03/06	The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026	AQ
26/05	Bulletin from the Annual General Meeting of Alzinova AB (publ)	AQ
25/05	The subscription price for warrants of series TO4 in Alzinova has been determined to SEK 0.32 and the exercise period begins today	AQ